Royalty financing deepens exposure to small cell lung cancer revenues

1. Royalty Pharma struck a deal worth up to 950 million dollars to buy into Amgen’s DLL3 directed bispecific for SCLC (small cell lung cancer).

2. The transaction ties steady royalty payments to a drug that has already shown strong survival gains over chemotherapy.

Royalty Pharma announced on August 25 that it would acquire a royalty stream from Amgen’s DLL3 targeting bispecific for SCLC, reported by Reuters. The company paid 885 million dollars upfront and could add another 65 million dollars later, giving it about 7 percent of global sales outside Greater China, according to the company statement. Imdelltra, the drug in question, posted 215 million dollars in sales in the first half of 2025 and is forecast to exceed 2.8 billion annually by 2035, highlighted again in Reuters coverage. Late-stage trials showed a 40 percent reduction in risk of death compared with chemotherapy, a figure that underpins why investors see such long-term value. For oncologists, nothing about how the drug is used changes, but the financing shows just how much confidence markets have in its staying power. Royalty Pharma’s model means it can capture returns from already approved therapies without taking on early development risk. That money, in turn, often gets recycled into younger biotech programs that may someday reach the clinic. Some analysts argue that this stabilizes access because royalty holders want steady patient use and reimbursement rather than price shocks. The royalty extends through 2041, giving Amgen decades of shared incentive to keep the therapy relevant. For physicians, the takeaway is not about dollars, but about the strong signal that SCLC finally has a therapy attracting long-term confidence. The deal also underscores how financial structures, not just clinical results, influence which drugs get pushed forward. And it raises a broader question: will more blockbuster oncology drugs see similar financing strategies?

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.